TY - JOUR
T1 - Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis
AU - Komatsu, Noriko
AU - Win, Stephanie
AU - Yan, Minglu
AU - Cong-Nhat Huynh, Nam
AU - Sawa, Shinichiro
AU - Tsukasaki, Masayuki
AU - Terashima, Asuka
AU - Pluemsakunthai, Warunee
AU - Kollias, George
AU - Nakashima, Tomoki
AU - Takayanagi, Hiroshi
N1 - Funding Information:
Conflict of interest: The Department of Osteoimmunology is an endowed department, supported by unrestricted grants from AYUMI Pharmaceutical, Chugai Pharmaceutical, MIKI HOUSE, and Noevir. Copyright: © 2021, American Society for Clinical Investigation. Submitted: August 14, 2020; Accepted: January 27, 2021; Published: March 15, 2021. Reference information: J Clin Invest. 2021;131(6):e143060. https://doi.org/10.1172/JCI143060.
Funding Information:
We are grateful to M. Reth (Max Planck Institute) for providing Mb1-Cre mice. We thank T. Nitta, K. Okamoto, K. Matsuda, M. Komag-amine, Y. Okada, L. Danks, T. Asano, K. Kusubata, Y. Ogiwara, and K. Kubo for thoughtful discussion and valuable assistance. This work was supported in part by a grant for the Grants-in-Aid for Specially Promoted Research (15H05703), Scientific Research B (18H02636), Challenging Research (18K19438, 20K21515), Young Scientists (19K18943) from the Japan Society for the Promotion of Science (JSPS), AMED under grant number JP20ek0410073, and AMED-CREST under grant number JP20gm1210008.
Publisher Copyright:
© 2021 American Society for Clinical Investigation. All rights reserved.
PY - 2021/3/15
Y1 - 2021/3/15
N2 - In rheumatoid arthritis (RA), osteoclastic bone resorption causes structural joint damage as well as periarticular and systemic bone loss. Periarticular bone loss is one of the earliest indices of RA, often preceding the onset of clinical symptoms via largely unknown mechanisms. Excessive osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL) expressed by synovial fibroblasts causes joint erosion, whereas the role of RANKL expressed by lymphocytes in various types of bone damage has yet to be elucidated. In the bone marrow of arthritic mice, we found an increase in the number of RANKL-expressing plasma cells, which displayed an ability to induce osteoclastogenesis in vitro. Genetic ablation of RANKL in B-lineage cells resulted in amelioration of periarticular bone loss, but not of articular erosion or systemic bone loss, in autoimmune arthritis. We also show conclusive evidence for the critical contribution of synovial fibroblast RANKL to joint erosion in collagen-induced arthritis on the arthritogenic DBA/1J background. This study highlights the importance of plasmacell RANKL in periarticular bone loss in arthritis and provides mechanistic insight into the early manifestation of bone lesion induced by autoimmunity.
AB - In rheumatoid arthritis (RA), osteoclastic bone resorption causes structural joint damage as well as periarticular and systemic bone loss. Periarticular bone loss is one of the earliest indices of RA, often preceding the onset of clinical symptoms via largely unknown mechanisms. Excessive osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL) expressed by synovial fibroblasts causes joint erosion, whereas the role of RANKL expressed by lymphocytes in various types of bone damage has yet to be elucidated. In the bone marrow of arthritic mice, we found an increase in the number of RANKL-expressing plasma cells, which displayed an ability to induce osteoclastogenesis in vitro. Genetic ablation of RANKL in B-lineage cells resulted in amelioration of periarticular bone loss, but not of articular erosion or systemic bone loss, in autoimmune arthritis. We also show conclusive evidence for the critical contribution of synovial fibroblast RANKL to joint erosion in collagen-induced arthritis on the arthritogenic DBA/1J background. This study highlights the importance of plasmacell RANKL in periarticular bone loss in arthritis and provides mechanistic insight into the early manifestation of bone lesion induced by autoimmunity.
UR - http://www.scopus.com/inward/record.url?scp=85102703849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102703849&partnerID=8YFLogxK
U2 - 10.1172/JCI143060
DO - 10.1172/JCI143060
M3 - Article
C2 - 33720039
AN - SCOPUS:85102703849
SN - 0021-9738
VL - 131
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 6
M1 - e143060
ER -